Laurel, MD, May 7, 2007 – BioServe today strengthened its senior management team with the appointment of Kevin Krenitsky, M.D. as Chief Executive Officer. Krenitsky is a highly respected 15-year veteran of the life sciences industry, bringing a wealth of experience in building and managing global biotechnology operations.
“Kevin’s impressive range of experience in diagnostics, pre-clinical and clinical pharma, along with his in depth knowledge of our recently acquired Genomics Collaborative bio-banking business makes him the perfect fit to lead BioServe into the future,” said Rama Modali, Founder and President, BioServe. “Kevin’s operational experience along with his successful experience in launching new products and service offerings will be instrumental in growing BioServe’s global business. We are pleased that Kevin has joined BioServe and look forward to his contributions to the team.”
Prior to joining BioServe, Dr. Krenitsky was the Chief Executive Officer of Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. Prior to that he served as Senior Vice President and Division Head at SeraCare Life Sciences’ Genomics Collaborative Division (GCI) where he managed all worldwide pharmaceutical R&D collaborations. Before GCI was acquired by Seracare Life Sciences, Dr. Krenitsky acted as the company’s Medical Director responsible for spearheading the development of GCI’s global network of five hundred-plus clinical sites on four continents. During his tenure at GCI, Dr. Krenitsky was instrumental in developing several hundred agreements with dozens of major pharmaceutical, biotechnology, and diagnostic companies worldwide. Dr Krenitsky received his M.D. from Jefferson Medical College.
Dr. Krenitsky commented, “I am extremely excited to join BioServe, a company that has forged a stellar reputation for genomic analysis among many of the world’s leading researchers. With the addition of the Genomics Collaborative bio-bank to the company’s comprehensive services, BioServe is on track to become the leader in helping researchers discover and validate a new generation of superior diagnostic and therapeutic targets.”